comprehensive -WSS

comprehensive

author：comprehensive 2025-10-01 20:15:11 - browse：78

Golden brain and DNA spiral illustration. -- biotech coverage from STAT — Adobe

The dream of being able to pluck a cell therapy off of a freezer shelf and speedily give it to cancer patients is materializing in the cancer world. Now, a new biotech hopes to do the same for patients with neurological conditions.

Kenai Therapeutics closed a $82 million Series A round Thursday co-led by Cure Ventures, The Column Group, and sovereign wealth fund Alaska Permanent Fund Corp. The San Diego-based biotech has big plans for that money — it’s already identified its lead drug candidate for people with Parkinson’s disease, and plans to move into a clinical trial within the next year.

Kenai — pronounced key-nigh — is developing therapies that use induced pluripotent stem cells, or iPSCs. These highly versatile organisms are derived from skin or blood cells and can be transformed into any type of cell. In Parkinson’s, the idea is that these cells would replace damaged neurons.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Massive project maps cells in human brain in unprecedented detail

focus

WSS

Massive project maps cells in human brain in unprecedented detail

Abortion clinic in Cancun will cater to Americans

Don't let 'shelved assets' gather dust. Make them into new lifesaving drugs

Life sciences deals on track to hit lowest point since 2017

European regulators consider appeal over Amylyx ALS drug

Peter Marks talks Operation Warp Speed for Rare Diseases

leisure time

comprehensive

focus

Hepatitis C has a cure — but many Americans still lack access to it

A fraught question for the kids of Alzheimer’s: Is it coming for us?

Medical leaders decry Supreme Court decision on affirmative action

European regulators consider appeal over Amylyx ALS drug

Wildfire smoke exposes gaps in outdoor worker protections

Eight reasons why you should get an updated Covid vaccine

Sports medicine is finally prioritizing gender equality

Diversify hospital leadership teams to protect BIPOC patient health

The cancer drug shortage isn’t new — and neither are the solutions

STAT Executive Editor Rick Berke on STAT's 8th birthday

explore

European regulators recommend Amylyx's ALS drug be rejected

STAT Executive Editor Rick Berke on STAT's 8th birthday

Humana CEO Bruce Broussard to step down in 2024

Don't let 'shelved assets' gather dust. Make them into new lifesaving drugs

FDA approves Recor Medical high blood pressure device

FDA approves Recor Medical high blood pressure device

hotspot

hotspot

focus

entertainment